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Synopsis 22 
Objectives: Antimicrobial susceptibility data for Chlamydia trachomatis are lacking. 23 
Methodologies for susceptibility testing in C. trachomatis are not well-defined, standardised 24 
or performed routinely owing to its intracellular growth requirements. We sought to 25 
develop an assay for the in vitro susceptibility testing of C. trachomatis isolates from two 26 
patient cohorts with different clinical outcomes.   27 
Methods: Twenty-four clinical isolates (11 from persistently infected and 13 from 28 
successfully treated patients) were overlaid with media containing two-fold serial dilutions 29 
of azithromycin or doxycycline. After incubation, aliquots were removed from the stock 30 
inoculum (SI) and each antimicrobial concentration for total RNA extraction, complementary 31 
DNA generation and real-time PCR. The MIC was defined as the lowest antimicrobial 32 
concentration where a 95% reduction in transcription was evident in comparison with the SI 33 
for each isolate. 34 
Results: MICs of azithromycin were comparable for isolates from the two patient groups 35 
(82% ≤0.25 mg/L persistently infected and 100% ≤0.25 mg/L successfully treated patients). 36 
Doxycycline MICs were at least two-fold lower for isolates from the successfully treated 37 
patients (53.9% ≤0.064 mg/L) than for the persistently infected patients (100% ≥0.125 mg/L) 38 
(p=0.006, Fisher’s exact test). Overall, 96% of isolates gave reproducible MICs when re-39 
tested.  40 
Conclusions: A reproducible assay was developed for antimicrobial susceptibility testing of 41 
C. trachomatis. MICs of azithromycin were generally comparable for the two different 42 
patient groups. MICs of doxycycline were significantly higher in the persistently infected 43 
patients. However, interpretation of elevated MICs in C. trachomatis is extremely 44 
challenging in the absence of breakpoints, or wild-type and treatment failure MIC 45 
distribution data. 46 
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Introduction 62 
Chlamydia trachomatis is the most prevalent bacterial sexually transmitted infection 63 
worldwide with 202,546 diagnoses in England in 2016. 1  Current first-line recommended 64 
treatment regimens for uncomplicated infection are 1 g stat azithromycin, or 100 mg  65 
doxycycline twice a day for seven days. 2  Whilst the efficacy of these treatments is 66 
considered to be extremely high, 3, 4 treatment failure with 1 g stat azithromycin has been 67 
demonstrated in C. trachomatis-positive men with non-gonococcal urethritis and rectal 68 
chlamydia and in women not at risk of re-infection. 5-7 Further reports of treatment failure 69 
have been described in patients where the risk of re-infection is low. 8-15  There are a 70 
number of possible reasons why patients may remain positive for chlamydia after 71 
treatment: non-adherence to the treatment regimen; re-infection from a new or untreated 72 
partner; inadequate exposure to the antimicrobial as a result of host pharmacokinetics or 73 
short duration of treatment, 16 and heterotypic or homotypic antimicrobial resistance. 74 
Heterotypic resistance, also known as phenotypic switching, occurs when a heterogeneous 75 
population of both resistant and susceptible organisms replicate from a single predecessor. 76 
7 It is not genetically inherited but is a result of adaptations by the bacteria to make them 77 
less susceptible to the antimicrobial e.g. induction of slow growing, non-replicative or 78 
persistent forms in the presence of antibiotic, which revert back to replicating forms once 79 
the antibiotic pressure has been removed resulting in a relapse in infection. Homotypic 80 
antimicrobial resistance is, by contrast, genetically inherited.  81 
At high bacterial loads, e.g. as found in patients with symptoms of urethritis, 17 C. 82 
trachomatis has been shown to exhibit heterotypic resistance. 18, 19 Confirmed phenotypic 83 
decreased susceptibility to antimicrobials of clinical significance has been reported rarely in 84 
C. trachomatis. 9, 11, 20, 21 Stable genotypic resistance to antimicrobials in clinical practice has 85 
yet to be documented in human urogenital C. trachomatis infection. 16 However very little is 86 
known about the susceptibility profiles of circulating strains because antimicrobial 87 
susceptibility assays are not routinely performed and the methodology is neither 88 
standardised nor well-defined. 7, 18, 22  89 
We describe the development of a robust antimicrobial susceptibility testing methodology 90 
(adapted from Storm et al 23), and report susceptibility data for azithromycin and 91 
doxycycline  for a cohort of C. trachomatis isolates from patients who were persistently 92 
infected with C. trachomatis. Susceptibility data are also presented for C. trachomatis 93 
isolates from a group of control patients who were C. trachomatis-positive at initial 94 
presentation and were then confirmed to have been treated successfully.          95 
 Methods 96 
Patient recruitment 97 
As reported previously 24 patients with persistent C. trachomatis infections were recruited 98 
from sexual health clinics across England and Wales. Patients were deemed to have a 99 
persistent infection if they had tested positive at least twice by a C. trachomatis-specific 100 
assay (e.g. a nucleic acid amplification test, NAAT), had fully adhered to the prescribed 101 
treatment regimens in line with current guidelines 2 (including any abstinence periods) and 102 
were assessed to be at low risk of re-infection.  Risk of re-infection was categorised using 103 
self-declared sexual contact behaviour in the time since initial diagnosis, reported via a 104 
clinician-completed questionnaire.  Patients were considered at low risk of re-infection 105 
following treatment if they had: a) no sexual contact, b) protected sexual contact only, or c) 106 
unprotected sexual contact with a partner who had not tested positive or who had tested 107 
positive, but had been treated.  These groups were designated categories 1, 2 and 3 108 
respectively. Clinical data collected for some of the patients in this report were reported 109 
previously. 24 110 
Control isolates were collected from patients who had been treated for C. trachomatis 111 
infection in line with current UK guidelines 2 and had a negative test-of-cure by NAAT at 112 
least 30 days later.   113 
Ethical approval 114 
Patients with persistent infections were referred as part of an enhanced surveillance 115 
programme and therefore ethical approval was not sought or required.  Public Health 116 
England has permission to handle these data under the Health Service (Control of Patient 117 
Information) regulation 2002, overseen by the Confidentiality Advisory Group.    118 
Control patients were recruited through a sexual health clinic, ethics reference number 119 
13/WM/0088. 120 
Culture methods 121 
Stock inoculum culture 122 
Clinical specimens (persistently infected group: 6 specimens from male patients [5 urethral 123 
swabs and 1 rectal swab] and 5 specimens from female patients [4 cervical swabs and 1 124 
urethral swab; successfully treated group: 2 specimens from male patients [1 urethral swab 125 
and one swab from an unknown site and 11 specimens from female patients [3 cervical 126 
swabs, 8 self-collected vaginal swabs were inoculated on to confluent McCoy cell mono-127 
layers in shell vials.  Shell vials were centrifuged at 2300 x g for 1 h at 35oC and were then 128 
incubated for 4 h at 35oC in 5% CO2.  The inoculum was then aspirated and the infected 129 
mono-layer was overlaid with Dulbecco’s Modified Eagles Medium (DMEM, Gibco, Hemel 130 
Hempstead, U.K.) supplemented with 10% foetal bovine serum (Gibco), 200 mM L-131 
glutamine (Sigma, Gillingham, U.K.), 1 mg/L cycloheximide (Sigma), 100 mg/L gentamicin 132 
(Gibco), 25 U/mL nystatin (Sigma) and 100 mg/L vancomycin (Sigma).  Shell vials were 133 
incubated for 48 h at 35oC in 5% CO2 to produce a stock inoculum of each strain for 134 
antibiotic susceptibility testing assays.  Inclusion forming units (IFUs) were visualised after 135 
staining with the MicroTrak® Chlamydia trachomatis culture confirmation test (Trinity 136 
Biotech, Newmarket, U.K.).  137 
Susceptibility assays 138 
MICs of azithromycin and doxycycline were determined as follows; confluent McCoy cell 139 
monolayers in 48-well plates were overlaid with the stock inoculum of each strain (103-105 140 
inclusion forming units per well), plates were centrifuged for 1 h at 1350 x g and 35oC and 141 
were then incubated at 35oC, 5% CO2 for 4 h to facilitate infection.  Wells were aspirated 142 
and overlaid with two-fold serial dilutions of antimicrobial (0.125-2 mg/L azithromycin or 143 
0.064-1 mg/L doxycycline) in supplemented DMEM (as above).  An antimicrobial-free 144 
control was included for each strain to allow identification of assay failure.  Due to the lack 145 
of known azithromycin- or doxycycline- resistant control isolates of C. trachomatis, a 146 
susceptible control C. trachomatis isolate (from a successfully treated patient, isolate 314) 147 
was used in the azithromycin assays, and the tetracycline-resistant C. suis strain R19 25 was 148 
used in the doxycycline assays.  Plates were then incubated for 48 h at 35oC in 5% CO2. 149 
RNA extractions and cDNA generation 150 
The RNeasy Plus Mini Kit (QIAgen, Manchester, U.K.) was used as per the manufacturer’s 151 
instructions to extract total RNA from aliquots of culture media collected from each 152 
antibiotic concentration and negative control at varying stages during the susceptibility 153 
assay, namely the initial inoculum (P0) and after the 48 h incubation with antimicrobial (P1).  154 
Complementary DNA (cDNA) was reverse transcribed from the total RNA (2 µL per reaction) 155 
using the Quantitect reverse transcription kit (QIAgen) as per manufacturer’s instructions.  156 
This kit includes a step for removing contaminating genomic DNA negating the need for a 157 
separate DNaseI digestion. 158 
Real Time-PCR to detect transcription and interpretation of MIC endpoint 159 
cDNA was used as template for real time PCR (RT-PCR) on the RotorGene (QIAgen) platform 160 
(primer and probe sequences in Table 1) to quantify the C. trachomatis transcripts and allow 161 
assignment of an MIC of each antimicrobial for each strain.  The method described by Storm 162 
et al 23 was modified to facilitate use of an L2 internal control, prepared in-house, for 163 
transcript quantification. In place of the omp2 gene target a predicted virulence factor on 164 
the C. trachomatis cryptic plasmid was used as the chlamydia specific target. 26  The McCoy 165 
cell Β-actin gene (inhibition control) and the C. suis R19 23S rRNA gene were detected 166 
qualitatively only where appropriate. To increase assay sensitivity each target was run as a 167 
separate reaction.  168 
Twenty-five microliter reactions were prepared for each target in HotStarTaq master mix 169 
(QIAgen).  Primer and probe sequences can be found in Table 1. C. trachomatis-specific 170 
target: 200 nM Ct-Forward primer, 320 nM Ct-Reverse primer, 200 nM Ct-Probe and 10 µL 171 
cDNA. McCoy cell β-actin-specific target: 100 nM McCoy-Forward primer, 100 nM McCoy-172 
Reverse primer, 24 nM McCoy-Probe and 5 µL cDNA. C. suis-specific target: 200 nM R19-173 
Forward primer, 200 nM R19-Reverse primer, 200 nM R19-Probe and 5 µL cDNA. Reactions 174 
were run on the RotorGene platform (QIAgen) using the following programme: initial 175 
denaturation and Taq activation step of 95oC for 10 minutes followed by 50 cycles of 95oC 176 
for 30 seconds, 60oC for 40 seconds (acquiring in the green [FAM, C. trachomatis-specific 177 
PCR], yellow [JOE, McCoy cell-specific PCR] or red [Cy5, C. suis-specific PCR] channel) and 178 
72oC for 40 seconds. A standard curve was generated using a previously quantified C. 179 
trachomatis L2 cryptic plasmid positive control on each C. trachomatis-specific PCR run to 180 
allow quantification of transcripts.  As described by Storm et al 23 the MIC was assigned to 181 
the lowest antimicrobial concentration where a ≥95% reduction in transcription was 182 
observed after a passage in the presence of antimicrobial (P1) in comparison with the initial 183 
inoculum (P0) for each strain. RT-PCR was used only for MIC assignment to negate 184 
subjectivity of immunofluorescent staining interpretation. 185 
Statistical analysis 186 
Geometric means of the azithromycin and doxycycline MICs were calculated and linear 187 
regression was used to analyse the relationship between the MICs and the different patient 188 
groups. As absolute MICs were not available for a number of isolates (i.e. MICs were ≤ or ≥) 189 
then MIC values a doubling dilution above or below the recorded MIC e.g. ≤0.064 mg/L was 190 
analysed as 0.032 mg/L and ≥1 mg/L was analysed as 2 mg/L). Fisher’s exact test was used 191 
to compare azithromycin MICs ≤0.25 mg/L versus MICs >0.25 mg/L and doxycycline MICs 192 
≤0.064 mg/L versus MICs >0.064 mg/L in the persistently infected and successfully treated 193 
patient groups respectively.  Results for both tests were deemed significant if the p value 194 
was ≤0.05.  195 
Results 196 
Isolate retrieval 197 
Isolates were retrieved from eleven patients with persistent C. trachomatis infections that 198 
met the inclusion criteria outlined previously (five in category 1, two in category 2 and four 199 
in category 3). In addition, isolates were retrieved from thirteen control patients with linked 200 
negative test-of-cure samples.  201 
MIC data 202 
Azithromycin MICs were ≤0.25 mg/L for 81.8% (9/11) of the isolates from patients with 203 
persistent infections and for 100% (13/13) of isolates from the successfully treated control 204 
patients (Table 2, Table 3). The azithromycin geometric mean MICs were 0.127 mg/L and 205 
0.071 mg/L for isolates from the persistently positive group and the successfully treated 206 
patient group, respectively. Azithromycin MICs for two isolates (18.2%) in the persistently 207 
infected group were 2 mg/L and 0.5 mg/L (Table 2, Table 3). No difference (Fisher’s exact 208 
test, p = 0.3; linear regression p = 0.1) was observed between the azithromycin MICs for 209 
isolates from the persistently infected patients compared with those for isolates from the 210 
successfully treated patients. The MICs of doxycycline for the isolates from the successfully 211 
treated patient group were significantly lower than MICs for isolates from the persistently 212 
infected patient group (Fisher’s exact test, p = 0.006); doxycycline MICs for 7/11 (63.6%) 213 
isolates from patients with persistent infections were 0.125 mg/L, and for the remaining 214 
four isolates (36.4%) were ≥1 mg/L. The doxycycline MICs for most (7/13, 53.9%) isolates in 215 
the successfully treated group were ≤0.064 mg/L, at least two-fold lower than the lowest 216 
MICs for isolates from the treatment failure group. The doxycycline MICs for the five 217 
remaining isolates from the successfully treated group were 0.125 mg/L (3 isolates), 0.25 218 
mg/L (1 isolate) and 1 mg/L (3 isolates) (Table 2). These patients were all treated with 219 
azithromycin 1 g only. The doxycycline geometric mean MICs were 0.322 mg/L and 0.097 220 
mg/L for isolates from the persistently positive group and the successfully treated patient 221 
group, respectively (p = 0.032). 222 
Assay reproducibility 223 
To investigate the robustness of the susceptibility testing methodology, 11 (45.8%) isolates 224 
chosen at random (8 [8/11, 72.7%] from the persistently infected and 3 [23.1%] from the 225 
successfully treated patient groups) were repeat tested on the azithromycin assay and the 226 
MICs from both assay runs compared.  All (11/11, 100%) repeat MICs were in complete 227 
agreement with initial testing. Thirteen (54.2%) isolates chosen at random (5 [5/11, 45.5%] 228 
from the persistently infected and 8 [8/13, 61.5%] from the successfully treated patient 229 
groups) were repeat tested on the doxycycline assay. Twelve (12/13, 92.3%) of the repeat 230 
MICs were in agreement with the initial MIC data. For one isolate in the successfully treated 231 
group the repeat MIC for doxycycline (≤0.064 mg/L) was at least four-fold (two dilution 232 
steps) lower than the initial MIC (≥0.25 mg/L). During initial validation of the assays the 233 
range of antimicrobial concentrations tested were altered as considered appropriate based 234 
on the MICs obtained. The initial assay for this isolate had an antibiotic range tested of 235 
0.064 – 0.25 mg/L doxycycline whilst later assays were tested up to 1 mg/L doxycycline. 236 
Collectively 23/24 (95.8% [confidence interval: 76.9-99.8%]) of the isolates that were 237 
retested on either assay gave reproducible MIC. 238 
 239 
 240 
Discussion 241 
We have adapted and further developed an assay for phenotypic in vitro antimicrobial 242 
susceptibility testing of C. trachomatis. The assay was used to test clinical isolates sourced 243 
from two distinct patient groups, one with persistent C. trachomatis infections and the 244 
other with C. trachomatis infections successfully treated following first-line recommended 245 
therapy (i.e. 1 g stat azithromycin). Clinical isolates from both groups were assayed against 246 
azithromycin and doxycycline. The assay methodology produced reproducible MICs of both 247 
antimicrobials when isolates were retested, with 95.8% of isolates giving identical MICs. The 248 
exception was an MIC obtained in a ‘failed’ repeat assay that was at least four-fold lower 249 
than for the initial assay.  250 
MICs of doxycycline for the isolates from patients who had persistent infections were 251 
significantly higher than for isolates from successfully treated patients. A number of the 252 
patients in the persistently infected group had been treated with doxycycline in addition to 253 
azithromycin (Table 2). The doxycycline MICs for these isolates varied from 0.125 mg/L, 254 
which is comparable to the majority of the MICs for isolates from the successfully treated 255 
group, to >1 mg/L which is significantly less susceptible. However, the doxycycline MICs for 256 
two isolates in the successfully treated group were also 1 mg/L and neither of these patients 257 
were treated with doxycycline regimens.  The significance of these raised MICs is unclear.  258 
There did not appear to be a difference between the MICs of azithromycin for isolates from 259 
the two patient groups. Indeed, whilst the majority of patients in the persistently infected 260 
group were treated at least twice with 1 g azithromycin stat regimens (Table 2) the MICs for 261 
the isolates from these patients were mostly within a two-fold dilution compared with the 262 
MICs for the isolates from the successfully treated patients and the ‘susceptible’ control 263 
strain, 314.  There were two isolates in the persistently infected group with azithromycin 264 
MICs at least two dilutions higher than control strain 314 and the successfully treated 265 
patient group. Interestingly, both of these patients had only been treated once with 1 g 266 
azithromycin stat regimens. Overall, this suggests that the antibiotic pressure exerted by re-267 
treatment with the same antibiotic did not select for increased MICs (reduced susceptibility) 268 
in these isolates. It may be hypothesised that heterotypic resistance induced in vivo may 269 
account for the similarity of MIC, but difference in clinical outcome seen with these patients 270 
if re-infection can truly be excluded, as asserted. 271 
What is clear from the data presented is that much further work is needed to understand 272 
the relevance of the MICs obtained from both patients who resolve infection after 273 
treatment with first-line therapies and from patients who remain infected. In vitro 274 
susceptibility testing can only be performed with cultured isolates, which for C. trachomatis, 275 
are a rare commodity in the current diagnostic environment. Whilst molecular detection of 276 
known markers associated with antimicrobial resistance can infer genotypic susceptibility, 277 
emerging resistance can only be detected through in vitro susceptibility testing. Therefore 278 
access to isolates of clinically significant pathogens, such as C. trachomatis, is imperative.  279 
For many organisms, such as Neisseria gonorrhoeae, there are internationally recognised 280 
standard protocols for antimicrobial susceptibility testing. No such standardisation exists for 281 
C. trachomatis 18 and antimicrobial susceptibility testing is particularly complex as it is an 282 
obligate intracellular organism requiring tissue cell culture for in vitro growth. 18 This, 283 
combined with the biphasic nature of the C. trachomatis lifecycle (where the extracellular 284 
phase is non-replicative), introduces a potential for assay variability not seen for other 285 
organisms. Suchland et al. (2003) and Wang et al (2005) described a range of factors that 286 
may influence the MICs for C. trachomatis in vitro, such as cell line used, inoculum size and 287 
time from where infection occurs to addition of the antimicrobial. Interpretation of the 288 
endpoint of the MIC assay can also be problematic. Traditionally, immunofluorescent 289 
staining of tissue cultures has been commonly used to identify aberrant chlamydial 290 
inclusions, but this method is time-consuming and subjective. In addition, failure to visualise 291 
C. trachomatis inclusions in in vitro cultures does not exclude a viable state that can 292 
proliferate once the antibiotic pressure has been removed. 27  293 
To negate subjectivity and to detect all viable organisms, we adapted a method previously 294 
described by Storm et al. (2005), which monitored the presence of mRNA transcripts in pre- 295 
and post-antimicrobial treated C. trachomatis cultures. Whilst the efficiency of reverse 296 
transcriptase PCR is known to be variable, the reproducibility of the MICs presented in this 297 
report indicate that this procedure was standardised as much as possible. The Storm assay 298 
was adapted to include detection of a predicted virulence factor gene on the C. trachomatis 299 
cryptic plasmid in place of the original C. trachomatis omp2 gene. The cryptic plasmid is 300 
constitutively expressed throughout the C. trachomatis life-cycle and, whilst the number of 301 
copies of the plasmid carried can vary between different strains of C. trachomatis, 28 isolates 302 
were compared with themselves only. It was assumed that the plasmid copy number 303 
remained stable within a strain however it is possible that they may vary during different 304 
lifecycle stages and/or when challenged with antimicrobial; investigation of this was beyond 305 
the scope of this study but is a recognised potential limitation. We also increased the time 306 
that infected cultures were incubated prior to application of the antimicrobials from two 307 
hours, as described in Storm et al. (2005), to four hours to allow infections to establish more 308 
completely before challenge. Clean cell lines were screened for the presence of 309 
contaminants prior to inoculation as part of routine tissue culture maintenance and all 310 
infected cell line work was carried out in the presence of multiple antimicrobial/antifungal 311 
agents. However, as the isolates were clinical in origin it cannot be fully excluded that no 312 
other organism was present in the tissue culture at the time of susceptibility testing,     313 
Despite development of a reproducible assay, there are limitations to this work. 314 
Interpretation of our MIC results was difficult as no susceptibility or resistance breakpoints 315 
exist for C. trachomatis and there is very limited data 29, 30 regarding the wild-type 316 
distributions of susceptibility to azithromycin and doxycycline for circulating strains. Due to 317 
the dearth of susceptibility data for this organism, how in vitro MICs correlate with 318 
treatment success or failure in the patient is poorly understood.  Indeed, when the results 319 
presented in this report are taken into account i.e. evidence of consistent in vivo phenotypic 320 
resistance to azithromycin in the patients persistently infected with C. trachomatis without 321 
evidence of reduced susceptibility of the isolate in vitro, the picture becomes even more 322 
complex.  323 
Given the move to the use of doxycycline as the preferred first-line therapy for NGU, in 324 
which C. trachomatis is the most commonly identified pathogen, 31 understanding the 325 
relevance of the raised doxycycline MICs in isolates from the persistently infected patient 326 
group is important.  Particularly as doxycycline may in the future be given as prophylaxis to 327 
men who have sex with men as PrEP for bacterial sexually transmitted pathogens 32 and the 328 
impact of this increased doxycycline usage on C. trachomatis MICs is unknown. The high-329 
level of assay reproducibility suggests that whilst the majority of strain MICs differed by only 330 
one doubling dilution, the difference (p=0.006) was unlikely related to the susceptibility 331 
testing methodology and an MIC shift towards less-susceptible was observed in the 332 
persistently infected patient group.  However the root cause of this shift and its impact on 333 
clinical outcome is unclear. A larger observational case control study is required to generate 334 
data to allow appropriate antimicrobial stewardship. 33 This data may strengthen the case 335 
for recommendation of a test of cure in all patient groups.   336 
In addition, a number of physiological factors, such as the host inflammatory response, that 337 
would form part of natural infection resolution (in addition to antimicrobial therapy) and 338 
individual patient pharmacokinetics that cannot be replicated in in vitro cell culture systems 339 
must also be considered. It is therefore difficult to hypothesise how representative an MIC 340 
alone would be as a marker of likelihood of treatment success. There are also few data 341 
available regarding how in vitro culturing of isolates affects the organisms’ susceptibility to 342 
antimicrobials. The patients who were persistently infected with C. trachomatis were 343 
exposed to a minimum of two rounds of antimicrobial therapy, but viable organisms 344 
remained. These patients were thought unlikely to have been re-infected, but this cannot be 345 
excluded completely. Antimicrobial susceptibility assays were carried out secondary to the 346 
primary isolation from the clinical specimen. As a result, it was necessary to re-culture each 347 
isolate from an archived aliquot. It is possible that multiple passages in tissue culture in the 348 
absence of antimicrobial challenge could have affected the MIC obtained especially if 349 
surviving antimicrobial therapy in the patient led to a fitness cost.  The authors recognise 350 
this as a weakness of the study and would recommend progressive processing through 351 
primary isolation and antimicrobial susceptibility testing to limit time in culture as an ideal. 352 
Further to this, the length, complexity and cost of the testing procedure is not amenable to 353 
large-scale phenotypic testing over a wide antibiotic concentration range. Processing of 354 
isolates from recovery from archive to obtaining MIC results took on average 15 working 355 
days.  Nevertheless, we determined MICs of two therapeutically-relevant antibiotics for 24 356 
clinical C. trachomatis strains. Any large-scale antimicrobial resistance surveillance in C. 357 
trachomatis would need to take advantage of molecular techniques to screen for genetic 358 
markers of reduced susceptibility in addition to in vitro susceptibility testing if reliable 359 
indicators could be identified. Reassuringly, in a recent large-scale genome sequencing 360 
study of global C. trachomatis isolates, no known molecular markers of antimicrobial 361 
resistance were detected. 34 362 
In summary, a reproducible method for phenotypic antimicrobial susceptibility testing of C. 363 
trachomatis has been described. The assay was employed for the analysis of a small number 364 
of clinical isolates from two groups of patients who had very different treatment outcomes. 365 
The azithromycin MICs for the majority of strains within the persistently-positive group 366 
were comparable with those for strains in the successfully treated group. However, the 367 
MICs of doxycycline were higher in the persistently infected than in the successfully treated 368 
patient group. Antimicrobial susceptibility testing and interpretation of elevated MICs in C. 369 
trachomatis is extremely challenging in the absence of breakpoints. Further work to 370 
generate wild-type and treatment failure distribution data should be undertaken.  371 
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Table 1. Primer and probe sequences used for RT-PCR 507 
 Sequence 5’-3’ Reference 
Ct-Forward GGA TTG ACT CCG ACA ACG TAT TC  
Chen26 Ct-Reverse ATC ATT GCC ATT AGA AAG GGC ATT 
Ct-Probe FAM-TTA CGT GTA GGC GGT TTA GAA AGC GG-BHQ-1 
McCoy-Forward TCA CCC ACA CTG TGC CCA TCT ACG A  
Storm23 McCoy-Reverse TGG TGA AGC TGT AGC CAC GCT 
McCoy-Probe JOE-TAT GCT CTC CCT-(TAMRA)-CAC GCC ATC CTG 
CGT 
R19-Forward CCT GCC GAA CTG AAA CAT CTT A Modified from 
Pantchev35 R19-Reverse CCC TAC AAC CCC TCG CTT CT 
R19-Probe Cy5-CGA GCG AAA GGG GAA GAG CCT AAA CC-BHQ3 
 508 
 509 
 510 
 511 
 512 
 513 
 514 
 515 
 516 
Table 2. Summary of the characteristics of C. trachomatis strains isolated from patients who 517 
were treatment failures (Pt.) or successfully treated (Ctrl). 518 
    
Treatment prescribed MIC (mg/L) 
   
omp1 
genotype 
Azithromycin 
1 g stat 
Doxycycline 
100 mg bd 
7 days 
Other Azithromycin Doxycycline 
P
er
si
st
e
n
tl
y 
in
fe
ct
e
d
 
C
at
. 1
 
Pt.1 G X1 X2   ≤0.125 0.125 
Pt.2 E X2     ≤0.125 >1 
Pt.3 E X3 
X1(14 
days) 
  0.125 0.125 
Pt.4 E X1 X1   2 0.125 
Pt.5 J X2 X1 
500 mg stat 
azithromycin then 
unknown dose od 4 
days 
≤0.125 0.125 
C
at
. 2
 
Pt.6 D X2     ≤0.125 0.125 
Pt.7 G X2 X1   ≤0.125 0.125 
C
at
. 3
 
Pt.8 E X2     ≤0.125 0.125 
Pt.9 E X2     0.25 1 
Pt.10 E X2 X1   ≤0.125 >1 
Pt.11 E  X1   
500 mg erythromycin 
qd 7 days 
0.5 >1 
 
Su
cc
e
ss
fu
lly
 t
re
at
e
d
 c
o
n
tr
o
ls
 
Ctrl.1 F x1     ≤0.125 ≤0.064 
 
Ctrl.2 E x1     ≤0.125 ≤0.064 
 
Ctrl.3 E x1     ≤0.125 0.125 
 
Ctrl.4 E x1     ≤0.125 ≤0.064 
 
Ctrl.5 E x1     ≤0.125 0.125 
 
Ctrl.6 D x1     ≤0.125 ≤0.064 
 
Ctrl.7 E x1     ≤0.125 1 
 
Ctrl.8 F x1     ≤0.125 0.125 
 
Ctrl.9 E x1     ≤0.125 0.064 
 
Ctrl.10 D x1     ≤0.125 0.064 
 
Ctrl.11 D x1     0.25 0.25 
 
Ctrl.12 E x1     ≤0.125 1 
 
Ctrl.13 E x1     ≤0.125 ≤0.064 
 
 
   
    Control 
strains 
314* D       ≤0.125 - 
R19∆ N/A       - ≥1 
* isolate from a successfully treated patient, ∆ tetracycline resistant C. suis strain R1925.  519 
Persistently infected patients were categorised based on their likelihood of re-infection through a self-declared 520 
sexual behaviour questionnaire. Cat. 1 – no sexual contact since initial diagnosis, Cat. 2 – protected sexual 521 
contact only and Cat. 3 – unprotected sexual contact with a regular partner who had also tested positive and 522 
had been treated or a partner that did not test positive. Stat – statim, od – once daily, bd – bi-daily, qd – 523 
quarter-daily, N/A – not applicable. 524 
Table 3. MICs of azithromycin and doxycycline obtained from isolates from two different C. 525 
trachomatis-infected patient cohorts.  526 
  
Persistently 
infected 
(n=11) 
Successfully 
treated 
(n=13) 
 
A
zi
th
ro
m
yc
in
 
≤0.25 
9 13 no 
81.8 100 % 
>0.25 
2 0 
 
18.2 0 
 
D
o
xy
cy
cl
in
e ≤0.064 
0 7 
 
0 53.9 
 
>0.064 
11 6 
 
100 46.2 
 
Geometric mean of MICs: Azithromycin - 0.127 mg/L (persistently infected) and 0.071 mg/L 527 
(successfully treated), Doxycycline – 0.322 mg/L (persistently infected) and 0.097 mg/L (successfully 528 
treated). 529 
